Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism

por Dylla, Douglas E, Xie, Litao, Michele, Daniel E, Kunz, Stefan, McCray, Paul B
Publicado 2011

Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021

por Martinez, Anthony, Khan, Tipu, Dylla, Douglas E., Marcinak, John, Collins, Michelle, Saget, Brad, Conway, Brian
Publicado 2023

Awareness and Epidemiology of Chronic Hepatitis C Virus Infections in Florida

por Thomas, Emmanuel, Cheng, Wei-Han, Dylla, Douglas E., Marx, Steven E., Carabino, Jana, Xu, Qingqing
Publicado 2021

Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study

por Martinez, Anthony, Cheng, Wei-Han, Marx, Steven E., Manthena, Shivaji, Dylla, Douglas E., Wilson, Lauren, Thomas, Emmanuel
Publicado 2023

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharm...

por Mukherjee, Dwaipayan, Collins, Michelle, Dylla, Douglas E., Kaur, Jatinder, Semizarov, Dimitri, Martinez, Anthony, Conway, Brian, Khan, Tipu, Mostafa, Nael M.
Publicado 2023

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection

por Flamm, Steven L., Kort, Jens, Marx, Steven E., Strezewski, John, Dylla, Douglas E., Bacon, Bruce, Curry, Michael P., Tsai, Naoky, Wick, Nicole
Publicado 2020

Lentiviral Vector Gene Transfer to Porcine Airways

por Sinn, Patrick L, Cooney, Ashley L, Oakland, Mayumi, Dylla, Douglas E, Wallen, Tanner J, Pezzulo, Alejandro A, Chang, Eugene H, McCray, Paul B
Publicado 2012

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/...

por Gane, Edward, de Ledinghen, Victor, Dylla, Douglas E., Rizzardini, Giuliano, Shiffman, Mitchell L., Barclay, Stephen T., Calleja, Jose Luis, Xue, Zhenyi, Burroughs, Margaret, Gutierrez, Julio A.
Publicado 2021

Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017–2019

por Reau, Nancy, Sulkowski, Mark S., Thomas, Emmanuel, Sundaram, Vinay, Xu, Qingqing, Cheng, Wei-Han, Marx, Steven E., Hayes, Oscar A., Manthena, Shivaji R., Chirikov, Viktor, Dylla, Douglas E., Brooks, Hannah, Carabino, Jana M., Saab, Sammy
Publicado 2021

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

por Forns, Xavier, Feld, Jordan J., Dylla, Douglas E., Pol, Stanislas, Chayama, Kazuaki, Hou, Jinlin, Heo, Jeong, Lampertico, Pietro, Brown, Ashley, Bondin, Mark, Tatsch, Fernando, Burroughs, Margaret, Marcinak, John, Zhang, Zhenzhen, Emmett, Amanda, Gordon, Stuart C., Jacobson, Ira M.
Publicado 2021

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

por Feld, Jordan J., Forns, Xavier, Dylla, Douglas E., Kumada, Hiromitsu, de Ledinghen, Victor, Wei, Lai, Brown, Robert S., Flisiak, Robert, Lampertico, Pietro, Thabut, Dominique, Bondin, Mark, Tatsch, Fernando, Burroughs, Margaret, Marcinak, John, Zhang, Zhenzhen, Emmett, Amanda, Jacobson, Ira M.
Publicado 2022

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

por Zamor, Philippe J., Brown, Ashley, Dylla, Douglas E., Dillon, John F., Luetkemeyer, Anne F., Feld, Jordan J., Mutimer, David, Ghalib, Reem, Crown, Eric, Lovell, Sandra S., Hu, Yiran, Moreno, Christophe, Nelson, David R., Colombo, Massimo, Papatheodoridis, Georgios, Rockstroh, Juergen K., Skoien, Richard, Lawitz, Eric, Jacobson, Ira M.
Publicado 2021